MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Boomerang Medical, a women-led bioelectronic medicine company, has announced the enrollment of the first patients in its U.S. clinical trial evaluating the use of nerve stimulation as a potential treatment for Crohn’s disease and ulcerative colitis, the two most common forms of Inflammatory Bowel Disease (IBD). This study marks a significant milestone for the company, which was granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) earlier this year for its bioelectronic technology targeting the treatment of IBD.
Previous ArticleMerck to buy Prometheus Biosciences for about $11 billion (CNBC)
Keep Reading
Add A Comment